Cyclobenzaprine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
NEW YORK, April 24, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that 50 percent of the planned total number of participants have been... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 24, 2020 Category: Pharmaceuticals Source Type: clinical trials

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
Condition:   Pain, Acute Interventions:   Drug: Fixed Dose Combination;   Drug: Etodolac;   Drug: Cyclobenzaprine Sponsor:   Apsen Farmaceutica S.A. Not yet recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2017 Category: Research Source Type: clinical trials